Free tool
FAERS Monitor: Darzalex Faspro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761145 or its brand name (Darzalex Faspro, Daratumumab and Hyaluronidase-Fihj). Reports on generic versions are filed under their own applications.
Reports
3,064
Serious
1,414
46% of reports
Hospitalization
462
Death reported
121
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue225
- product dose omission issue223
- off label use210
- rash163
- diarrhoea141
- nausea118
- dyspnoea105
- neuropathy peripheral104
- neutropenia91
- plasma cell myeloma90
- death86
- dizziness76
- pyrexia76
- pneumonia74
- white blood cell count decreased70
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 105 |
| 2021 | 328 |
| 2022 | 511 |
| 2023 | 521 |
| 2024 | 556 |
| 2025 | 570 |
| 2026 | 471 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,095 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| plasma cell myelomaSignal | 90 | 15.9 | 12.9 | 1,239 |
| neuropathy peripheralSignal | 104 | 7.5 | 6.2 | 583 |
| product dose omission issueSignal | 223 | 5.2 | 4.6 | 764 |
| neutropeniaSignal | 91 | 4.6 | 3.8 | 254 |
| white blood cell count decreasedSignal | 70 | 4.4 | 3.5 | 184 |
| rashSignal | 163 | 2.6 | 2.2 | 158 |
| fatigue | 225 | 2.0 | 1.7 | 113 |
| off label use | 210 | 1.6 | 1.4 | 55 |
| pneumonia | 74 | 1.6 | 1.3 | 15 |
| pyrexia | 76 | 1.5 | 1.2 | 13 |
| diarrhoea | 141 | 1.5 | 1.3 | 24 |
| dyspnoea | 105 | 1.3 | 1.1 | 6 |
| dizziness | 76 | 1.0 | 0.8 | 0 |
| nausea | 118 | 1.0 | 0.9 | 0 |
| death | 86 | 0.7 | 0.6 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.